source
- Roche signs $2.5 billion deal with Hanmi for experimental obesity drug targeting muscle lossRoche's Genentech unit has agreed to acquire global rights (outside South Korea) to Hanmi's clinical-stage urocortin-2 analog, HM17321, as part of a deal valued up to $2.5 billion. The agreement i…
- Early Alert: Nitric Oxide Delivery System Issue from NOxBOXThe NOxBOX NOxBOXi System may leak oxygen during inhaled nitric oxide therapy